Novel Abs targeting the N‐terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile‐acid‐related side‐effects

Hepatocellular carcinoma (HCC) is a common and particularly fatal form of cancer for which very few drugs are effective. The fibroblast growth factor 19 (FGF19) has been viewed as a driver of HCC development and a potential Ab target for developing novel HCC therapy. However, a previously developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huisi, Zheng, Sanduo, Hou, Xinfeng, Liu, Ximing, Du, Kaixin, Lv, Xueyuan, Li, Yulu, Yang, Fang, Li, Wenhui, Sui, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226213/
https://www.ncbi.nlm.nih.gov/pubmed/32061104
http://dx.doi.org/10.1111/cas.14353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226213/
https://www.ncbi.nlm.nih.gov/pubmed/32061104
http://dx.doi.org/10.1111/cas.14353

Ejemplares similares